| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 977 | 2020 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 965 | 2020 |
| Four distinct trajectories of tau deposition identified in Alzheimer’s disease JW Vogel, AL Young, NP Oxtoby, R Smith, R Ossenkoppele, ... Nature medicine 27 (5), 871-881, 2021 | 545 | 2021 |
| Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease JW Vogel, Y Iturria-Medina, OT Strandberg, R Smith, E Levitis, AC Evans, ... Nature communications 11 (1), 2612, 2020 | 413 | 2020 |
| Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders R Ossenkoppele, GD Rabinovici, R Smith, H Cho, M Schöll, O Strandberg, ... Jama 320 (11), 1151-1162, 2018 | 400 | 2018 |
| Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease S Janelidze, E Stomrud, R Smith, S Palmqvist, N Mattsson, DC Airey, ... Nature communications 11 (1), 1683, 2020 | 363 | 2020 |
| Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease S Palmqvist, H Zetterberg, N Mattsson, P Johansson, ... Neurology 85 (14), 1240-1249, 2015 | 355 | 2015 |
| Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease JB Pereira, S Janelidze, R Smith, N Mattsson-Carlgren, S Palmqvist, ... Brain 144 (11), 3505-3516, 2021 | 326 | 2021 |
| Orexin loss in Huntington's disease Å Petersén, J Gil, MLC Maat-Schieman, M Björkqvist, H Tanila, IM Araujo, ... Human molecular genetics 14 (1), 39-47, 2005 | 311 | 2005 |
| Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease N Franzmeier, J Neitzel, A Rubinski, R Smith, O Strandberg, ... Nature communications 11 (1), 347, 2020 | 278 | 2020 |
| Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease R Ossenkoppele, R Smith, T Ohlsson, O Strandberg, N Mattsson, PS Insel, ... Neurology 92 (6), e601-e612, 2019 | 277 | 2019 |
| Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease N Mattsson-Carlgren, E Andersson, S Janelidze, R Ossenkoppele, P Insel, ... Science advances 6 (16), eaaz2387, 2020 | 269 | 2020 |
| Associations of plasma phospho-tau217 levels with tau positron emission tomography in early Alzheimer disease S Janelidze, D Berron, R Smith, O Strandberg, NK Proctor, JL Dage, ... JAMA neurology 78 (2), 149-156, 2021 | 244 | 2021 |
| Synaptic dysfunction in Huntington’s disease: a new perspective R Smith, P Brundin, JY Li Cellular and Molecular Life Sciences CMLS 62, 1901-1912, 2005 | 223 | 2005 |
| Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline R Ossenkoppele, A Pichet Binette, C Groot, R Smith, O Strandberg, ... Nature medicine 28 (11), 2381-2387, 2022 | 217 | 2022 |
| Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission … R Ossenkoppele, R Smith, N Mattsson-Carlgren, C Groot, A Leuzy, ... JAMA neurology 78 (8), 961-971, 2021 | 216 | 2021 |
| 18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease N Mattsson, M Schöll, O Strandberg, R Smith, S Palmqvist, PS Insel, ... EMBO molecular medicine 9 (9), 1212-1223, 2017 | 200 | 2017 |
| 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers R Smith, A Puschmann, M Schöll, T Ohlsson, J Van Swieten, M Honer, ... Brain 139 (9), 2372-2379, 2016 | 187 | 2016 |
| Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease JB Pereira, S Janelidze, R Ossenkoppele, H Kvartsberg, A Brinkmalm, ... Brain 144 (1), 310-324, 2021 | 181 | 2021 |
| Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders A Leuzy, R Smith, R Ossenkoppele, A Santillo, E Borroni, G Klein, ... JAMA neurology 77 (8), 955-965, 2020 | 176 | 2020 |
